Vaxine’s current lead product is its Advax range of vaccine adjuvants and vaccines based on these adjuvants. Advax is now in advanced human clinical development as a component of universal influenza, therapeutic hepatitis B and therapeutic allergy vaccines Vaxine is internally developing. Advax adjuvants have been shown to enhance the efficacy of a very wide range of vaccines against pneumococcus, typhoid fever, shigella, tuberculosis, Japanese encephalitis, West Nile virus, malaria, onchocercosis, HIV, tuberculosis, SARS, MERS, anthrax, RSV, HSV2, and Ebola, amongst others. Vaxine is also involved in projects seeking to apply Advax to development of vaccines against non-infectious diseases, including allergy, cancer, drug addiction and Alzheimer’s disease. For example, the Alzheimer’s disease vaccine works by by targeting abnormal Abeta and tau proteins. Much of this vaccine development is conducted in collaboration with global collaborators which include organisations including the National Institutes of Health, the US army and USAID as well as vaccine companies and academic research groups.